Cargando…
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation
BACKGROUND: Patients with inflammatory bowel disease (IBD) and healthy controls received primary SARS-CoV-2-mRNA vaccination and a booster after six months. Anti-TNF-α-treated patients showed significantly lower antibody (Ab) levels and faster waning than α4β7-integrin-antagonist recipients and cont...
Autores principales: | Garner-Spitzer, Erika, Wagner, Angelika, Gudipati, Venugopal, Schoetta, Anna-Margarita, Orola-Taus, Maria, Kundi, Michael, Kunert, Renate, Mayrhofer, Patrick, Huppa, Johannes B., Stockinger, Hannes, Carsetti, Rita, Gattinger, Pia, Valenta, Rudolf, Kratzer, Bernhard, Sehgal, Al Nasar Ahmed, Pickl, Winfried F., Reinisch, Walter, Novacek, Gottfried, Wiedermann, Ursula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485594/ https://www.ncbi.nlm.nih.gov/pubmed/37672867 http://dx.doi.org/10.1016/j.ebiom.2023.104788 |
Ejemplares similares
-
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease
por: Wagner, Angelika, et al.
Publicado: (2022) -
Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin’s lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma
por: Byford, Elliot T., et al.
Publicado: (2018) -
SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year
por: Garner-Spitzer, Erika, et al.
Publicado: (2022) -
Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients
por: Lu, Xiuyuan, et al.
Publicado: (2021) -
HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh
por: Chandrakasan, Shanmuganathan, et al.
Publicado: (2022)